These additional new compounds are progressing through a panel of cell-based screening assays which are designed to identify the most potent, druggable compound(s) in the series. The screening is progressing well and it is anticipated that a subset will soon be identified for progression to an animal model of the Covid-19 disease.
The Company has identified its top three anti-SARS-CoV-2 compounds.
These compounds are now progressing through preliminary safety studies as well as bioavailability studies in mice.
Looks like druggable compounds could be ready by mid year phase 1 trial, poorer countries can't vaccinate in time to open up for international travel but we can give you tablet to cure that infection.
Ann: Lead Series for SARS-COV-2 Program, page-58
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.001(3.70%) |
Mkt cap ! $24.36M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.7¢ | 2.6¢ | $4.605K | 176.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 499991 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 189421 | 3 |
View Market Depth
| Last trade - 12.24pm 20/08/2024 (20 minute delay) ? |
| BIT (ASX) Chart |